If you suspect you've accidentally injected semaglutide into muscle: Do not administer an extra dose to compensate Continue your regular dosing schedule for future injections Monitor for unusual symptoms but understand that occasional technique errors are unlikely to significantly compromise overall treatment Pay attention to blood glucose levels , especially if you also take insulin or sulfonylureas, as these combinations increase hypoglycemia risk Contact your healthcare provider promptly if you experience: Severe or persistent abdominal pain (potential sign of pancreatitis) Signs of allergic reaction (rash, swelling, difficulty breathing) Symptoms of hypoglycemia (if on insulin or sulfonylureas) Signs of infection at the injection site While an occasional intramuscular injection is not typically a medical emergency, proper technique for future injections is important for consistent medication delivery and therapeutic effect
Kapali J, Kabat BE, Schmidt KL, Stallings CE, Tippy M, Jung DO, Edwards BS, Nantie LB, Raeztman LT, Navratil AM, Ellsworth BS
Moreover, whether this observed phenomenon of lean mass loss translates into an exacerbation of the frailty phenotype is unclear
Cosman R, Brown CS, DeBraganca KC, Khasraw M
Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play
